PIA
EGRX

Piedmont Investment Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Piedmont Investment Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,976
Closed -$150K – 2396
2018
Q2 		$150K Buy
+1,976
New +$124K 0.01% 964

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Piedmont Investment Advisors's EGRX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2018, closing a stake of 1,976 shares — an estimated $150K sold.

Piedmont Investment Advisors first reported a position in EGRX in Q2 2018 and held it in 1 quarter. The position peaked at $150K in Q2 2018. 189 funds tracked by Wall St. Rank hold EGRX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,976 Eagle Pharmaceuticals, Inc. shares in Q3 2018, an estimated $150K.
  • Piedmont Investment Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Eagle Pharmaceuticals, Inc. position peaked at $150K in Q2 2018.
  • 189 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.